Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria de Miguel Luken

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Pharmacology Research & Perspectives|June 23, 2020
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairmentKarthick Vishwanathan, Inmaculada Sanchez-Simon, Bhumsuk Keam, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Pharmacology Research & Perspectives|June 23, 2020
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairmentKarthick Vishwanathan, Inmaculada Sanchez-Simon, Bhumsuk Keam, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Pageof 1